Claritas Pharmaceuticals Inc V.CLAS.H

Alternate Symbol(s): CLAZF

Healthcare

Claritas Pharmaceuticals, Inc., formerly Kalytera Therapeutics Inc, is a biotechnology company that is focused on developing R-107 for the treatment of vaccine-resistant coronavirus disease (COVID) strains. The Company’s products in development include R-107 for coronavirus disease and Viral Infections, R-107 and Vaccines, and CLA-1816 for treatment of pain. R-107 is designed to defeat COVID viruses on contact. R-107 targets the Achilles heel of COVID, the spike protein on the surface of the virus. R-107 releases nitric oxide, which attaches to a specific amino acid on the spike protein, thereby disabling the spike protein. The CLA-1816 provides effective pain reduction, without the risks of addiction or respiratory suppression that exist with opioid analgesics. CLA-1816 strongly binds with and activates the alpha3 glycine pain receptor in the spine. The Company has leased a laboratory, office, and archival space in Beverly, Massachusetts.

TSXV:CLAS.H - Post by User

Claritas Pharmaceuticals Inc

Bullboard Posts

Post by gregoooon Oct 18, 2011 12:03pm

343 Views

Post# 19159414

Warrants

I see a bunch of warrants expire on the 26th - +130,000,000.

Well in block 27 to be spudded this week - maybe today.
Canaguay #1 workover not done yet - still planning. rate holding at around 600 bfpd.
Next well in block 21? environmental approval soon?
maybe a operational update comming over the next month.
Horden Lake sale - waiting on purchaser to finalize.

Bullboard Posts

Paramount Resources signs $3.32 billion asset sale